Article
Oncology
Jeroen A. A. van de Pol, Lisa George, Piet A. van den Brandt, Marcella M. L. L. Baldewijns, Leo J. Schouten
Summary: The study found that there are different impacts of body mass index (BMI) and smoking on the risk of clear-cell RCC (ccRCC) and papillary RCC (pRCC), while alcohol consumption is negatively associated with the risk of both. Hypertension is positively associated with the risk of both ccRCC and pRCC. The research also indicates significant differences in BMI, BMI change, and smoking duration among current smokers in terms of ccRCC and pRCC risk.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Editorial Material
Oncology
Elizabeth P. Henske, Liang Cheng, A. Ari Hakimi, Toni K. Choueiri, David A. Braun
Summary: Chromophobe renal cell carcinoma (ChRCC) is the second most common variant of non-clear cell renal cell carcinoma. ChRCC differs from clear cell RCC (ccRCC) in terms of genetics, genomics, metabolism, cell of origin, and response to targeted and immune therapies. The pathogenesis of ChRCC is not well understood, but current evidence suggests two potential mechanisms: mTORC1 hyperactivation through PTEN pathway mutations and mitochondrial dysfunction leading to oxidative stress.
Review
Biochemistry & Molecular Biology
Jacek Rysz, Beata Franczyk, Janusz Lawinski, Anna Gluba-Brzozka
Summary: Renal cell carcinoma is a group of malignant tumors of the renal cortex. Clear cell papillary renal cell carcinoma, a specific subtype, shares morphologic and genetic features with other subtypes but also has distinct clinical behavior. Differentiating clear cell papillary renal cell carcinoma from other subtypes is crucial for appropriate management.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Shaan Dudani, Guillermo de Velasco, J. Connor Wells, Chun Loo Gan, Frede Donskov, Camillo Porta, Anna Fraccon, Felice Pasini, Jae Lyun Lee, Aaron Hansen, Georg A. Bjarnason, Benoit Beuselinck, Sumanta K. Pal, Takeshi Yuasa, Nils Kroeger, Ravindran Kanesvaran, M. Neil Reaume, Christina Canil, Toni K. Choueiri, Daniel Y. C. Heng
Summary: This study found that patterns of metastasis vary between histologic subtypes of metastatic RCC and are associated with overall survival. The data highlight the clinical and biological variability between histologic subtypes and suggest that patterns of metastasis may reflect differences in underlying disease biology. Further research is encouraged to investigate differences in immune, molecular, and genetic profiles between metastatic sites and histologic subtypes.
Review
Cell Biology
Joao Lobo, Riuko Ohashi, Mahul B. Amin, Daniel M. Berney, Eva M. Comperat, Ian A. Cree, Anthony J. Gill, Arndt Hartmann, Santosh Menon, George J. Netto, Maria R. Raspollini, Mark A. Rubin, Puay Hoon Tan, Satish K. Tickoo, Toyonori Tsuzuki, Samra Turajlic, Ming Zhou, John R. Srigley, Holger Moch
Summary: The 5th edition of the WHO Classification of Tumours of the Urinary and Male Genital Systems introduces molecularly defined renal tumour subtypes, eliminates the subcategorization of papillary renal cell carcinoma (pRCC), includes emerging entities within the pRCC spectrum, introduces a category of 'other oncocytic tumours', accepts eosinophilic solid and cystic RCC as a new entity, and highlights the need for a reproducible grading system for chromophobe renal cell carcinoma (chRCC).
Article
Biochemistry & Molecular Biology
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini
Summary: The study aimed to investigate the effectiveness and tolerability of pembrolizumab-axitinib combination as a first-line treatment option for patients with chromophobe and papillary metastatic renal cell carcinoma (mRCC). The results showed that this combination therapy had a good response rate and tolerability in patients with chromophobe and papillary mRCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Marie Mikuteit, Sandra Steffens, Stefanie Zschaebitz, Michael Autenrieth, Wilko Weichert, Arndt Hartmann, Franziska Erlmeier
Summary: This study aimed to evaluate the prognostic impact of Trop2 expression in patients with chromophobe RCC. The results showed that Trop2 expression was not significantly associated with clinical attributes and survival rates in patients with chromophobe RCC.
Article
Urology & Nephrology
Giuseppe Rosiello, Carlotta Palumbo, Sophie Knipper, Angela Pecoraro, Stefano Luzzago, Pierre-Antoine St-Hilaire, Zhe Tian, Umberto Capitanio, Francesco Montorsi, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Pierre Karakiewicz
Summary: Metastatic patients with papillary renal cell carcinoma have poor survival outcomes regardless of treatment received. They are more likely to present with lymph node metastases compared to clear-cell renal cell carcinoma patients.
WORLD JOURNAL OF UROLOGY
(2021)
Article
Oncology
Marie Mikuteit, Stefanie Zschaebitz, Maximilian Erlmeier, Michael Autenrieth, Wilko Weichert, Arndt Hartmann, Sandra Steffens, Franziska Erlmeier
Summary: Gas6 expression is not associated with survival and other parameters of aggressiveness in chRCC. Further studies are needed.
Article
Biochemistry & Molecular Biology
Xiaoyi Du, Zhipeng Zhao, Xin Zhao, Hexi Wang, Li Jiang, Wei Tang
Summary: In this study, we analyzed the subtypes of ccRCC mediated by 8 TSGs contained in the 3p21.3 gene cluster and their effects on TME cell infiltration. A risk score model was established to predict prognosis and drug sensitivity. The hub gene NPRL2 was found to promote sunitinib sensitivity in ccRCC cells.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Oncology
Viktor Grunwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, Maria Jose Mendez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri
Summary: In the CLEAR study, treatment with lenvatinib plus pembrolizumab showed significantly improved efficacy compared to sunitinib as first-line treatment for advanced renal cell carcinoma. The treatment was effective regardless of the presence or absence of lung metastases, bone metastases, liver metastases, prior nephrectomy, or sarcomatoid features.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Xin Wang, Jiang-Hua Jia, Ming Zhang, Qing-Song Meng, Bo-Wen Yan, Zi-Yue Ma, Dong-Bin Wang
Summary: This study found that the upregulation of ADM enhanced the chemoresistance of sunitinib by inhibiting FDX1 expression through cuproptosis. Mechanistically, ADM activates the p38/MAPK signaling pathway to promote FOXO3 phosphorylation and its entry into the nucleus, resulting in the inhibition of FDX1 transcription and cell cuproptosis, ultimately promoting chemoresistance in ccRCC.
Article
Oncology
Kei Nagase, Takashi Akutagawa, Mihoko Rikitake-Yamamoto, Sayuri Morito, Maki Futamata, Shohei Tobu, Mitsuru Noguchi, Shuji Toda, Shigehisa Aoki
Summary: This study investigated the cellular and physical microenvironments of RCC, exploring their regulatory effects on RCC behavior. The results showed that adipose tissue, macrophages, and fluid flow influence the proliferative and invasive capacity of RCC cells, and these effects may be mediated through the extracellular signal-regulated kinase and p38 signaling pathways.
JOURNAL OF PATHOLOGY
(2021)
Article
Pathology
Sean R. Williamson
Summary: Clear cell papillary renal cell carcinoma is a distinct entity with recognizable morphological features, often small in size and showing consistent immunohistochemical markers. It shares similarities with extrarenal benign neoplasms and may be reclassified as a benign or low malignant potential neoplasm based on its clinical behavior and molecular characteristics.
Article
Oncology
Chenchen Feng, Yuqing Li, Kunping Li, Yinfeng Lyu, Wenhui Zhu, Haowen Jiang, Hui Wen
Summary: PFKFB4 was found to be significantly overexpressed in tumors compared to normal kidney, associated with advanced tumor grade, stage and poor prognosis. PFKFB4 overexpression impaired cell proliferation, migration, and wound healing. Targeting PFKFB4 showed promise in overcoming resistance to Sunitinib.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)